Thursday, June 6, 2019 - Not to be too cynical or anything, but if I were the CEO of a drug company the last thing I would want would be for the drug's underlying disease to be cured, especially if the drug was making billions of dollars each year in profits. People have inferred that Gilead Sciences, maker of the anti-HIV drug Truvada has made only a limited amount of the drug available, approximately one-fifth to HIV infected patients for free when they had pledged to do much more. According to the New York Times, "The drug is taken once daily to prevent infection with H.I.V., a strategy called pre-exposure prophylaxis, or PrEP. An estimated one million Americans are at risk for infection and should be taking the pills, but only about 270,000 are doing so." HIV health activists say that the high price of Truvada is what prevents AIDS from being cured. Gilead defends the high price as an integral part of the risk/reward equations that powers drug research. National Truvada attorneys believe persons and family members of persons who developed acute or chronic kidney problems and suffered from broken or brittle bones while taking Truvada may be eligible for real compensation for the pain, suffering, medical expenses, lost income and other damages suffered, by filing a claim against Gilead.
The Trump Administration recently struck a deal with Gilead Sciences, maker of the anti-HIV drug Truvada, to make the drug available for free to lower-income patients. Unfortunately, the effort is falling short and will not get the drug to those that need it but cannot afford it. HIV experts and activists are critical that Gilead is doing only enough to placate those in government and holding out the supply of the drug until their own replacement drug, Descovy, can be put into place. Gilead continues to sell Truvada for $20000 per year, a price that ensures that most lower and middle-income people will not be able to afford it and that the disease will continue to spread, a win/win situation for Gilead.
Gilead is also fighting hard to squash international generic tenofovir (Truvada) competition and to maintain their stranglehold on the HIV drug market. Truvada's patent is set to expire soon, exposing it to generic drug competition at one-tenth of the cost but Gilead has readied a Truvada replacement. Gilead routinely pressures the US government to keep low-cost generic HIV drugs made in India from the US Market. While Truvada costs $20,000 per year in the US it is available in Africa for only $60 per year. Next year Gilead will switch from Truvada to Descovy to extend their patent monopoly many years into the future and keep the price high.
Descovy contains a new version of tenofovir, the active ingredient in Truvada and that could be problematic for those that take it. Truvada has been linked with causing osteoporosis, a dangerous loss of bone density. The US Food and Drug Administration (FDA) recently warned Gilead Sciences for making false safety claims about the drug. Truvada patients suffering from osteoporosis may be eligible to file a claim against Gilead for failing to warn them of the drug's side effects.
OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The firm has represented thousands of persons in these and other products liability litigation, including DePuy hip replacement systems, which settled for $2.5 billion and Pradaxa internal bleeding, which settled for $650 million. The Onder Law Firm won over $300 million in four talcum powder ovarian cancer lawsuits in St. Louis to date and other law firms throughout the nation often seek its experience and expertise on complex litigation.